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Abstract
Abnormalities in liver function tests, including transient 
and self-limiting hypertransaminasemia, cholestatic 
disease and hepatitis, can develop during treatment 
with anti-tumour-necrosis-factor (TNF) therapy. The 
optimal management of liver injury related to anti-
TNF therapy is still a matter of debate. Although some 
authors recommend discontinuing treatment in case 
of both a rise of alanine aminotransferase more than 
5 times the upper limit of normal, or the occurrence 
of jaundice, there are no standard guidelines for the 
management of anti-TNF-related liver injury. Biblio-
graphical searches were performed in PubMed, using 
the following key words: inflammatory bowel disease 
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(IBD); TNF inhibitors; hypertransaminasemia; drug-
related liver injury; infliximab. According to published 
data, elevation of transaminases in patients with IBD 
treated with anti-TNF is a common finding, but resolu-
tion appears to be the usual outcome. Anti-TNF agents 
seem to be safe with a low risk of causing severe drug-
related liver injury. According to our centre experience, 
we found that hypertransaminasemia was a common, 
mainly self-limiting finding in our IBD cohort and was 
not correlated to infliximab treatment on both univari-
ate and multivariate analyses. An algorithm for the 
management of liver impairment occurring during anti-
TNF treatment is also proposed and this highlights the 
need of a multidisciplinary approach and suggests liver 
biopsy as a key-point in the management decision in 
case of severe rise of transaminases. However, hepatic 
injury is generally self-limiting and drug withdrawal 
seems to be an exception.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Key words: Inflammatory bowel disease; Tumour ne-
crosis factor inhibitors; Hypertransaminasemia; Drug-
related liver injury; Infliximab
Core tip: Anti-tumour-necrosis-factor (TNF) agents ap-
pear to be safe with a low risk of causing severe liver 
injury. Standard guidelines for the management of 
anti-TNF-related liver injury are lacking. Our approach, 
based on evidence from literature and our centre ex-
perience, highlights the need of a multidisciplinary ap-
proach and suggests liver biopsy as a key-point in the 
management decision. We particularly highlight that 
continuation of the anti-TNF treatment is usually pos-
sible, in view of the rarity of severe liver injury and the 
lack of alternative medical options in case of severe ac-
tive inflammatory bowel disease.
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INTRODUCTION
Inflammatory bowel diseases (IBD), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC), are a heterogenous 
group of  chronic immune disorders of  unclear aetiology. 
There are approximately 240000 patients with IBD in the 
United Kingdom (UC: 243/100000 = 146000 people; 
CD: 145/100000 = 87000 people)[1]. People affected by 
IBD show a life-time risk for surgery of  70%-80% and 
20%-30% for CD and UC, respectively[2-6].
Therapy for IBD is a rapidly evolving field with many 
new biological agents that have shown promising results. 
Therapeutic options for IBD include corticosteroids, 
aminosalicylates, antibiotics (i.e., metronidazole and cip-
rofloxacin), thiopurines (i.e., azathioprine and mercapto-
purine), methotrexate, ciclosporin, tacrolimus and anti-
tumour necrosis factor (TNF) agents[1].
TNF-α is an integral pro-inflammatory cytokine, 
which is produced by macrophages and promotes the re-
lease of  other inflammatory cytokines. It plays a key role 
in immune defense against infections and contributes to 
the development of  certain cancers[7,8]. In view of  its well 
known pro-inflammatory action, TNF-α has been identi-
fied as a key therapeutic target for treating inflammatory 
diseases including IBD[8].
The United States Food and Drug Administration 
(FDA) has approved several anti-TNF-α agents, such as 
infliximab (Remicade, Janssen), adalimumab (Humira, 
Abbott), etanercept (Enbrel, Amgen), certolizumab 
(Cimzia, UCB), and golimumab (Simponi, Janssen), for 
the treatment of  several immunological conditions[9-13].
Some placebo-controlled trials have shown that inflix-
imab[14,15], adalimumab[16-18] and certolizumab pegol[19] are 
efficacious in the treatment of  moderate-to-severe CD, 
both when used as first-line therapy and in patients who 
did not respond to standard treatment. Anti-TNF agents 
have been reported to achieve disease remission, to main-
tain the treatment response[15,20-22], to allow tapering of  
glucocorticoids[15,16] and to promote mucosal healing[23]. 
Infliximab is also effective in the treatment of  fistulizing 
CD[24] and, according to current data, early treatment with 
infliximab or adalimumab (within 4 wk after surgery) 
could prevent histologic and endoscopic recurrence after 
ileal resection[25,26].
As concerns UC, some randomized, controlled tri-
als have shown that infliximab[27], adalimumab[28,29] and 
golimumab[30] can induce and maintain clinical remission 
in patients with moderate-to-severe disease activity who 
failed to respond to standard therapy. In particular, data 
suggest that infliximab reduces the rate of  colectomy 
after one year from 17% in the placebo group to 10% 
in those treated with infliximab[31]. Adverse effects of  
anti-TNF agents include acute infusion reactions (10%), 
severe infusion reactions (less than 1%), including ana-
phylaxis, convulsions, erythematous rash, and hypoten-
sion, serum sickness and leukocytoclastic vasculitis (< 1 
per 1000 patients), neurologic events (e.g., demyelinating 
neuropathy) (< 1 event per 1000 patients), risk of  oppor-
tunistic infections, and reactivation of  latent tuberculosis 
and/or hepatitis B virus (HBV) infection[32]. According to 
some studies, the risk of  specific cancers (i.e., non-Hodg-
kin’s lymphoma, lung cancer, skin cancer, and others) 
may be increased by the combinations of  glucocorticoids, 
immunomodulators, and TNF inhibitors[32].
All of  the TNF-antagonists currently marketed have 
been associated with drug-induced liver injury (DILI)[33,34]. 
According to a FDA post-marketing surveillance pro-
gram, more than 130 reports of  hepatic damage resulting 
from either infliximab or etanercept treatment have been 
reported. Among these, seven cases showed a strong as-
sociation with the anti-TNF agents[35]. Of  relevance, the 
use of  TNF inhibitors has been associated with the risk 
of  reactivation of  viral hepatitis B, although the exact 
underlying mechanism is still far from being fully eluci-
dated. Accordingly, pre-treatment screening for hepatitis 
B is required prior to start anti-TNF therapy and vaccina-
tion should be encouraged in the non-immune high-risk 
patients[36]. In addition, TNF inhibitor therapy may result 
in a wide range of  liver abnormalities, including transient 
and self-limiting hypertransaminasemia, cholestatic dis-
ease and hepatitis.
The optimal management of  liver injury related to 
anti-TNF therapy is still a matter of  debate. Although 
some authors recommend discontinuation of  treatment 
in case of  both a rise of  alanine aminotransferase (ALT) 
of  more than five times the upper limit of  normal (ULN), 
or the occurrence of  jaundice[37-39], at present there are 
no standard guidelines for the management of  anti-TNF-
related liver injury. Herein, we propose an algorithm for 
the management of  liver impairment occurring during 
anti-TNF treatment, according to both current evidence 
from literature and our own centre experience.
LITeRaTURe seaRChes 
Bibliographical searches were performed in PubMed, us-
ing the following key words: inflammatory bowel disease; 
TNF inhibitors; hypertransaminasemia; drug-related liver 
injury; infliximab. Reference lists from studies selected by 
the electronic search were manually searched to identify 
further relevant reports. Reference lists from all available 
review articles, primary studies and proceedings of  major 
meetings were also considered. No language restriction 
was applied.
Regarding our own centre experience, 305 patients 
with a histologically confirmed diagnosis of  IBD were 
retrospectively evaluated. Laboratory and clinical data 
were retrieved from a database at Department of  Gastro-
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enterology, Royal Free Hospital, London. Patients with 
known liver related disease were excluded. Of  these 305 
patients, 176 consecutive patients were treated with inf-
liximab, between 2008 and 2013, at the standard regimen 
dose of  5 mg/kg at weeks 0, 2, 6 and every 8 wk thereaf-
ter. Baseline laboratory parameters were obtained the day 
before infliximab induction and full blood count and liver 
biochemistry were monitored every 8 wk thereafter. Liver 
enzymes were recorded until each patient’s last follow-
up. The same parameters were recorded from a control 
group of  IBD patients, who did not receive any anti-
TNF agent and were matched by gender, type of  IBD 
and duration of  follow-up to the study group.
WhaT Is aLReaDY KNOWN aBOUT 
LIVeR DYsFUNCTION DURING aNTI-TNF 
TReaTMeNT
Elevation of  ALT/AST, usually between 2 and 3xULN is 
not uncommon during anti-TNF treatment with a report-
ed prevalence of  37%-42% compared with 29%-36% 
in control groups[40], but rarely results in liver failure[41]. 
However, liver damage including hepatitis or cholesta-
sis might be a complication of  anti-TNF treatment[42-53] 
and cases of  acute liver failure[54-58], fulminant hepatitis 
B infection[36,57,58] as well as severe liver injury requiring 
emergency liver transplantation have been reported[39,59]. 
Induction of  auto-immune/immuno-mediated hepatitis 
in patients with IBD[60-71] has also been reported. Anti-
TNF hepatitis, although rare, might be a life-threatening 
complication, which needs to be promptly recognized 
and treated. However, according to a recent systematic 
review, these agents are generally considered to be safe in 
the majority of  patients, including those with underlying 
liver disease (i.e., chronic hepatitis C), whereas the risk 
of  activation of  hepatitis B needs to be taken into ac-
count[72,73].
The underlying mechanism for liver toxicity associ-
ated with anti-TNF remains to be elucidated. Pre-existing 
liver disease and concomitant potentially hepatotoxic 
drugs may increase the risk. Infliximab hepatitis seems to 
be sustained by an immuno-mediated mechanism, mim-
icking the characteristics of  autoimmune hepatitis type I, 
although a direct liver damage cannot be ruled out[48,50]. 
Additionally, anti-TNF treatment is known to induce 
lipid profile changes[74-77], which may be reflected in a 
increased risk of  liver steatosis, although the importance 
of  these alterations needs to be clarified in future studies. 
Furthermore, whether infliximab immuno-mediated liver 
injury may lead to chronic disease, or ultimately resolve 
with treatment withdrawal remains to be fully elucidated.
OUR CeNTRe eXPeRIeNCe (MaNUsCRIPT 
IN PRePaRaTION)
According to our centre experience, 176 IBD patients 
were treated with infliximab between 2008 and 2013, 
with a mean duration of  treatment of  23.1 ± 21.7 mo, 
and ALT increase was observed in 69 (39.2%) of  them, 
with spontaneous resolution in 76% of  cases. Approxi-
mately 50% of  these patients were taking immunomodu-
lators. When comparing the 67 patients who had elevated 
transaminases with the 107 patients on infliximab who 
showed persistent normal ALT, there were no statistically 
significant differences in terms of  age, gender, diagnosis 
(UC or CD) and use of  immunomodulators, aminosalicy-
lates or steroids. 36.2% of  patients with abnormal ALT 
during follow-up had elevated transaminases up to one 
year before infliximab induction, compared to 15% of  
those with normal liver enzymes (P = 0.002). The mean 
duration of  anti-TNF treatment was significantly longer 
in patients with abnormal liver enzymes than in the sub-
group of  patients with normal transaminases (29.5 mo vs 
11.5 mo, P < 0.0005). In multivariate analysis, abnormal 
ALT in the subgroup of  patients treated with infliximab 
was significantly associated with elevated ALT prior to 
infliximab induction (OR = 3.854, 95%CI: 1.800-8.251, P 
= 0.001) and longer duration of  infliximab treatment (OR 
= 1.030, 95%CI: 1.013-1.047, P = 0.001).
When considering a whole cohort of  305 IBD pa-
tients (176 patients treated with infliximab and 129 IBD 
patients matched for gender, type of  IBD and length of  
follow-up as a control group), hypetransaminasemia was 
found in 36.4% of  the patients and spontaneous resolu-
tion occurred in 73% of  cases. Univariate and multivari-
ate analysis showed that the treatment with immunomod-
ulators was correlated to increased transaminases (OR = 
2.666, 95%CI: 1.576-4.511, P < 0.001), whilst the use of  
infliximab, steroids or aminosalicylates, age, gender and 
diagnosis were not (P = NS).
Twelve patients treated with infliximab developed 
severe hypertransaminasemia (ALT > 3 x ULN). They 
were all screened for hepatitis A, B, C, for HIV and CMV 
serology and found negative. Immunoglobulin G, ferri-
tin, alpha1- antitrypsin, copper, ceruloplasmin levels and 
coeliac screening were also normal. Alcohol intake was 
excluded. Three patients had positive antinuclear antibod-
ies: one patient had concomitant lupus erythematosus 
(titer 1:80) and the remaining two showed a very low titer 
(1:40). Additionally, as they all had normal immunoglobu-
lins, normal other autoantibodies and only transient hy-
pertransaminasemia, they were not further investigated. A 
liver ultrasound was performed in all the patients, show-
ing fatty liver in 4 patients. A liver biopsy was done in 3 
out of  12 infliximab patients with persistent severe hyper-
transaminasemia and liver histopathology was suggestive 
of  DILI in 2 patients and non-alcoholic steatohepatitis in 
the remaining one. Of  the two patients with established 
DILI one was on infliximab monotherapy (which was 
discontinued) and one on combination of  infliximab and 
6-mercaptopurine (6-MP, which was subsequently dis-
continued). The 12 patients were carefully monitored and 
hypertransaminasemia spontaneously resolved in 11/12 
patients without discontinuation of  anti-TNF treatment, 
whilst infliximab was stopped only in the patient with a 
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WhaT We sUGGesT
In view of  the available literature and our own centre’s ex-
perience we suggest the following algorithm for the man-
agement of  liver impairment occurring during anti-TNF 
treatment (Figure 1).
What information should be given to patients?
All patients should be aware of  the potential problem of  
hepatotoxicity and should seek urgent medical advice in 
case they feel unwell or notice the presence of  jaundice. 
Moreover, alcohol intake should be reduced, as per cur-
rent recommendations[78].
What to do before starting anti-TNF medication?
Before starting anti-TNF treatment, all the patients 
should be investigated for previous liver disease including 
viral chronic hepatitis, auto-immune disorders, non alco-
holic fatty liver disease, history of  alcohol intake/abuse 
and/or of  illicit drug use. A baseline complete blood test 
including liver function tests and screening for hepatitis B, 
C and for HIV is advisable. Risk of  reactivation of  hepa-
titis B should be taken into account and HBV carriers 
confirmed diagnosis of  DILI on liver biopsy. 
CURReNT ReCOMMeNDaTIONs 
ReGaRDING MONITORING LIVeR 
FUNCTION WITh aNTI-TNF TheRaPY
The optimal management of  liver injury related to anti-
TNF therapy is still a matter of  debate and a multidisci-
plinary management is required.
According to previous case reports and a recent 
consensus statement[39,62], it was recommended that inf-
liximab therapy should be avoided or discontinued in pa-
tients with a raise of  aminotransferases more than three 
times the ULN and that liver function tests should be 
determined prior to anti-TNF treatment, after induction 
treatment and at least every four months while on main-
tenance treatment. However, the application of  the above 
mentioned precautions failed in systematic prevention of  
the development of  severe liver injury[54]. Furthermore, 
such stringent criteria might deny anti-TNF to many pa-
tients who might benefit from it due to the lack of  alter-
native therapeutic options.
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Investigations for previous liver disease (chronic 
hepatitis, auto-immune disorders, non alcoholic fatty 
liver disease, history of alcohol intake, drug history). 
Baseline complete blood test with liver function tests 
and screening for hepatitis B, C and for HIV 
HBV carriers should receive primary prophylaxis or 
should be carefully monitored
Anti-TNF treatment
Check LFTs every two weeks for eight weeks
LFTs normal LFTs abnormal
Monitor LFTs every 8 wk 
for the duration of therapy
Isolated raise of ALT < 3 
ULN without jaundice
Raise of ALT > 3 
ULN +/- bilirubin 
increase or 
jaundice onset
Check LFTs every two 
weeks up to resolution
Rule out all possible causes of elevated 
transaminases (viral hepatitis, alcohol 
intake, autoimmunity, drugs, coeliac 
disease, NAFLD, iron, copper)
Refer to 
Hepatologist
Liver biopsy
Liver US
Multidisciplinary 
approach.
Treatment 
discontinuation is rare
Figure 1  Proposed algorithm for the management of liver abnormalities occurring during anti-tumour necrosis factor treatment. TNF: Tumour necrosis 
factor; ALT: Alanine aminotransferase; LFT: Liver function tests; NAFLD: Non alcoholic fatty liver disease; US: Ultrasound; HBV: Hepatitis B virus; ULN: Upper limit of 
normal; HIV: Human immunodeficiency virus.
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should receive primary prophylaxis or should be carefully 
monitored[79].
What to do after starting anti-TNF medication?
Liver function tests should be regularly performed after 
starting anti-TNF therapy, every two weeks for the first 
eight weeks, and eight weekly thereafter.
In those patients receiving anti-TNF therapy and with 
abnormal transaminase levels, the first step is to rule out 
all other possible causes of  hypetransaminasemia, includ-
ing viral hepatitis, history of  alcohol abuse, auto-immune 
disorders, coeliac disease, non alcoholic fatty liver disease 
and drug history.
When facing with an increase of  ALT < 3 x ULN 
repeated monitoring is advisable, even if  further ac-
tion might not be required. On the contrary, in case of  
marked elevation of  ALT levels (> 3 x ULN) or alarm 
signs (e.g., rapid onset of  jaundice), a multidisciplinary 
approach is required. Further tests, including a liver ultra-
sound scan, should be requested and in case of  persistent 
elevated transaminases, a liver biopsy might be useful 
to confirm the diagnosis of  DILI or to exclude other 
potential aetiologies, possibly suitable for specific treat-
ment. Of  course, DILI represents a relevant cause of  
liver impairment with significant morbidity and mortal-
ity[80]. Early diagnosis of  DILI might be difficult[81,82] and 
is usually by exclusion[83]. Liver histology is considered 
helpful in strengthening the diagnosis or excluding other 
potential causes of  liver injury and a recent study provid-
ed a standardized framework for systematic review and 
classification of  pathological changes in liver biopsies[84]. 
Discontinuation of  the treatment might be considered, 
but the decision should be tailored to each single patient, 
given the rarity of  severe liver injury and the possibility 
of  a spontaneous resolution of  the elevation of  trans-
aminase levels. According to our centre experience, the 
spontaneous resolution of  hypetransaminasemia despite 
continuing anti-TNF treatment, might suggest that severe 
liver injury due to anti-TNF therapy, although possible, is 
rare.
CONCLUsION
In conclusion, we have highlighted the lack of  standard 
guidelines for the management of  anti-TNF-related liver 
injury and, differently from previous reviews, we have 
proposed a possible algorithm for its management ac-
cording to both evidence from literature and our own 
centre’s experience. Innovative aspects of  our approach, 
which are not present in the algorithm previously sug-
gested by Mancini et al[62], include: (1) a multidisciplinary 
approach for this subgroup of  patients, which requires 
a close interaction between Hepatologists and Gastro-
enterolgists; (2) the continuation of  the anti-TNF treat-
ment which is usually possible, in view of  the rarity of  
severe liver injury, the high percentage of  spontaneous 
regression of  the hypertransaminasemia and the lack of  
alternative medical options in case of  severe active IBD. 
The decision should be tailored to each single patient; (3) 
a liver biopsy which is advisable prior to stopping treat-
ment because it might be useful to confirm the diagnosis 
of  DILI or to exclude other possible aetiologies which 
might benefit from specific therapy; and (4) the exclusion 
of  other possible causes of  hypetransaminasemia which 
should also include history of  alcohol intake, coeliac 
disease screening[85] and careful evaluation of  drug intake 
(other than anti-TNF treatment).
In summary, elevation of  ALT in patients with IBD 
treated with anti-TNF is a common finding, but, even in 
case of  moderate or severe ALT abnormalities, resolution 
appears to be the usual outcome. Anti-TNF agents ap-
pear to be safe with a low risk of  causing severe DILI. In 
case of  severe hypertransaminasemia a multidisciplinary 
approach is recommended but drug withdrawal seems to 
be an exception due to the rarity of  severe liver injury.
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